Some studies have shown that disruption of the ATF7IP-SETDB1 complex in tumor cells can restore the expression of tumor antigens, which provides a rationale for cancer immunotherapy targeting SETDB1 or ATF7IP (Hu et al., 2021). Here, SETDB1 is linked to cancer.